Rankings
▼
Calendar
JAZZ Q2 2017 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$11B
Q2 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$394M
+3.5% YoY
Gross Profit
$366M
92.7% margin
Operating Income
$165M
41.8% margin
Net Income
$106M
26.8% margin
EPS (Diluted)
$1.72
QoQ Revenue Growth
+4.9%
Cash Flow
Operating Cash Flow
$135M
Free Cash Flow
$125M
Stock-Based Comp.
$27M
Balance Sheet
Total Assets
$4.8B
Total Liabilities
$2.6B
Stockholders' Equity
$2.2B
Cash & Equivalents
$239M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$394M
$381M
+3.5%
Gross Profit
$366M
$357M
+2.4%
Operating Income
$165M
$169M
-2.2%
Net Income
$106M
$111M
-5.1%
Revenue Segments
Xyrem
$298M
76%
Erwinaze And Erwinase
$49M
13%
Defitelio
$30M
8%
Other Products
$7M
2%
Prialt
$6M
1%
Geographic Segments
UNITED STATES
$357M
90%
Europe
$27M
7%
Other Countries
$10M
3%
← FY 2017
All Quarters
Q3 2017 →